Merck & Co Inc MRK released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine.
The trial evaluated the immunogenicity, tolerability, and safety of V116 compared to Pfizer Inc's PFE Prevnar 20 (PCV20) in adults who had not previously received a pneumococcal vaccine.
In adults 50 years of age and older (Cohort 1), V116 elicited non-inferior immune responses compared to PCV20 for all 10 serotypes common to both vaccines as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at Day 30.
In adults 18 to 49 (Cohort 2), V116 elicited non-inferior immune responses (immunobridged) compared to adults 50 to 64, as assessed by serotype-specific OPA GMTs 30 days post-vaccination.
Across both cohorts, V116 had a safety profile comparable to PCV20.
The V116 Phase 3 clinical development program comprises eight trials (n=8,830) investigating the safety, tolerability, and immunogenicity of V116 in various adult populations.
V116 utilizes the CRM197 vaccine carrier protein, produced using Ligand Pharmaceuticals Incorporated LGND patent-protected Pelican Expression Technology platform. If approved, Ligand is entitled to a royalty on worldwide net sales.
In July, Merck announced topline results from two Phase 3 trials evaluating V116 in vaccine-naïve and previously vaccinated individuals.
Price Action: MRK shares are down 0.84% at $100.58 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
